Hepatic 11β-hydroxysteroid dehydrogenase type 1 activity in obesity and type 2 diabetes using a novel triple tracer cortisol technique

Simmi Dube, Barbara Norby, Vishwanath Pattan, Ravi K. Lingineni, Ravinder Jit Singh, Rickey E. Carter, Ananda Basu, Rita Basu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aims/hypothesis: Dysregulation of 11β-hydroxysteroid dehydrogenase (11β-HSD) enzyme activities are implicated in the pathogenesis of obesity and insulin resistance. The aim of the study was to determine whether hepatic 11β-HSD type 1 (11β-HSD-1) enzyme activity differs in people with and without obesity and type 2 diabetes. Methods: We measured hepatic 11β-HSD-1 activity in the overnight fasted state in 20 lean non-diabetic participants (LND), 21 overweight/obese non-diabetic participants (OND) and 20 overweight/obese participants with type 2 diabetes (ODM) using a non-invasive approach. One mg doses of [9,12,12-2H3]cortisol (D cortisol) and [4-13C]cortisone ([13C]cortisone) were ingested, while [1,2,6,7-3H]cortisol ([3H] cortisol) was infused intravenously to enable concurrent measurements of first-pass hepatic extraction of ingested D cortisol and hepatic conversion of ingested [ 13C]cortisone to C13 cortisol derived from the ingested cortisone (a measure of 11β-HSD-1 activity in the liver) using an isotope dilution technique. One-way ANOVA models and Kruskal-Wallis tests were used to test the hypothesis. Results: Plasma D cortisol and C13 cortisol concentrations were lower in OND than in LND (p<0.05) over 6 h of the study. There was no difference (p=0.15) in C13 and D cortisol concentrations between OND and ODM and between LND and ODM for the same study period. Hepatic conversion of [ 13C]cortisone to C13 cortisol was similar between groups. Conclusions/interpretation: Hepatic conversion of [13C]cortisone to C13 cortisol did not differ between the groups studied. We conclude that hepatic 11β-HSD-1 activity is similar in individuals who are overweight/obese or who have type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)1446-1455
Number of pages10
JournalDiabetologia
Volume57
Issue number7
DOIs
StatePublished - 2014

Fingerprint

11-beta-Hydroxysteroid Dehydrogenases
Type 2 Diabetes Mellitus
Hydrocortisone
Obesity
Cortisone
Liver
Indicator Dilution Techniques
Enzymes
Isotopes
Insulin Resistance
Analysis of Variance

Keywords

  • 11β-Hydroxysteroid dehydrogenase
  • Diabetes
  • Obesity

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Hepatic 11β-hydroxysteroid dehydrogenase type 1 activity in obesity and type 2 diabetes using a novel triple tracer cortisol technique. / Dube, Simmi; Norby, Barbara; Pattan, Vishwanath; Lingineni, Ravi K.; Singh, Ravinder Jit; Carter, Rickey E.; Basu, Ananda; Basu, Rita.

In: Diabetologia, Vol. 57, No. 7, 2014, p. 1446-1455.

Research output: Contribution to journalArticle

Dube, Simmi ; Norby, Barbara ; Pattan, Vishwanath ; Lingineni, Ravi K. ; Singh, Ravinder Jit ; Carter, Rickey E. ; Basu, Ananda ; Basu, Rita. / Hepatic 11β-hydroxysteroid dehydrogenase type 1 activity in obesity and type 2 diabetes using a novel triple tracer cortisol technique. In: Diabetologia. 2014 ; Vol. 57, No. 7. pp. 1446-1455.
@article{e79b10b42dee485b8b271df25400c2d3,
title = "Hepatic 11β-hydroxysteroid dehydrogenase type 1 activity in obesity and type 2 diabetes using a novel triple tracer cortisol technique",
abstract = "Aims/hypothesis: Dysregulation of 11β-hydroxysteroid dehydrogenase (11β-HSD) enzyme activities are implicated in the pathogenesis of obesity and insulin resistance. The aim of the study was to determine whether hepatic 11β-HSD type 1 (11β-HSD-1) enzyme activity differs in people with and without obesity and type 2 diabetes. Methods: We measured hepatic 11β-HSD-1 activity in the overnight fasted state in 20 lean non-diabetic participants (LND), 21 overweight/obese non-diabetic participants (OND) and 20 overweight/obese participants with type 2 diabetes (ODM) using a non-invasive approach. One mg doses of [9,12,12-2H3]cortisol (D cortisol) and [4-13C]cortisone ([13C]cortisone) were ingested, while [1,2,6,7-3H]cortisol ([3H] cortisol) was infused intravenously to enable concurrent measurements of first-pass hepatic extraction of ingested D cortisol and hepatic conversion of ingested [ 13C]cortisone to C13 cortisol derived from the ingested cortisone (a measure of 11β-HSD-1 activity in the liver) using an isotope dilution technique. One-way ANOVA models and Kruskal-Wallis tests were used to test the hypothesis. Results: Plasma D cortisol and C13 cortisol concentrations were lower in OND than in LND (p<0.05) over 6 h of the study. There was no difference (p=0.15) in C13 and D cortisol concentrations between OND and ODM and between LND and ODM for the same study period. Hepatic conversion of [ 13C]cortisone to C13 cortisol was similar between groups. Conclusions/interpretation: Hepatic conversion of [13C]cortisone to C13 cortisol did not differ between the groups studied. We conclude that hepatic 11β-HSD-1 activity is similar in individuals who are overweight/obese or who have type 2 diabetes.",
keywords = "11β-Hydroxysteroid dehydrogenase, Diabetes, Obesity",
author = "Simmi Dube and Barbara Norby and Vishwanath Pattan and Lingineni, {Ravi K.} and Singh, {Ravinder Jit} and Carter, {Rickey E.} and Ananda Basu and Rita Basu",
year = "2014",
doi = "10.1007/s00125-014-3240-x",
language = "English (US)",
volume = "57",
pages = "1446--1455",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Hepatic 11β-hydroxysteroid dehydrogenase type 1 activity in obesity and type 2 diabetes using a novel triple tracer cortisol technique

AU - Dube, Simmi

AU - Norby, Barbara

AU - Pattan, Vishwanath

AU - Lingineni, Ravi K.

AU - Singh, Ravinder Jit

AU - Carter, Rickey E.

AU - Basu, Ananda

AU - Basu, Rita

PY - 2014

Y1 - 2014

N2 - Aims/hypothesis: Dysregulation of 11β-hydroxysteroid dehydrogenase (11β-HSD) enzyme activities are implicated in the pathogenesis of obesity and insulin resistance. The aim of the study was to determine whether hepatic 11β-HSD type 1 (11β-HSD-1) enzyme activity differs in people with and without obesity and type 2 diabetes. Methods: We measured hepatic 11β-HSD-1 activity in the overnight fasted state in 20 lean non-diabetic participants (LND), 21 overweight/obese non-diabetic participants (OND) and 20 overweight/obese participants with type 2 diabetes (ODM) using a non-invasive approach. One mg doses of [9,12,12-2H3]cortisol (D cortisol) and [4-13C]cortisone ([13C]cortisone) were ingested, while [1,2,6,7-3H]cortisol ([3H] cortisol) was infused intravenously to enable concurrent measurements of first-pass hepatic extraction of ingested D cortisol and hepatic conversion of ingested [ 13C]cortisone to C13 cortisol derived from the ingested cortisone (a measure of 11β-HSD-1 activity in the liver) using an isotope dilution technique. One-way ANOVA models and Kruskal-Wallis tests were used to test the hypothesis. Results: Plasma D cortisol and C13 cortisol concentrations were lower in OND than in LND (p<0.05) over 6 h of the study. There was no difference (p=0.15) in C13 and D cortisol concentrations between OND and ODM and between LND and ODM for the same study period. Hepatic conversion of [ 13C]cortisone to C13 cortisol was similar between groups. Conclusions/interpretation: Hepatic conversion of [13C]cortisone to C13 cortisol did not differ between the groups studied. We conclude that hepatic 11β-HSD-1 activity is similar in individuals who are overweight/obese or who have type 2 diabetes.

AB - Aims/hypothesis: Dysregulation of 11β-hydroxysteroid dehydrogenase (11β-HSD) enzyme activities are implicated in the pathogenesis of obesity and insulin resistance. The aim of the study was to determine whether hepatic 11β-HSD type 1 (11β-HSD-1) enzyme activity differs in people with and without obesity and type 2 diabetes. Methods: We measured hepatic 11β-HSD-1 activity in the overnight fasted state in 20 lean non-diabetic participants (LND), 21 overweight/obese non-diabetic participants (OND) and 20 overweight/obese participants with type 2 diabetes (ODM) using a non-invasive approach. One mg doses of [9,12,12-2H3]cortisol (D cortisol) and [4-13C]cortisone ([13C]cortisone) were ingested, while [1,2,6,7-3H]cortisol ([3H] cortisol) was infused intravenously to enable concurrent measurements of first-pass hepatic extraction of ingested D cortisol and hepatic conversion of ingested [ 13C]cortisone to C13 cortisol derived from the ingested cortisone (a measure of 11β-HSD-1 activity in the liver) using an isotope dilution technique. One-way ANOVA models and Kruskal-Wallis tests were used to test the hypothesis. Results: Plasma D cortisol and C13 cortisol concentrations were lower in OND than in LND (p<0.05) over 6 h of the study. There was no difference (p=0.15) in C13 and D cortisol concentrations between OND and ODM and between LND and ODM for the same study period. Hepatic conversion of [ 13C]cortisone to C13 cortisol was similar between groups. Conclusions/interpretation: Hepatic conversion of [13C]cortisone to C13 cortisol did not differ between the groups studied. We conclude that hepatic 11β-HSD-1 activity is similar in individuals who are overweight/obese or who have type 2 diabetes.

KW - 11β-Hydroxysteroid dehydrogenase

KW - Diabetes

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=84903518224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903518224&partnerID=8YFLogxK

U2 - 10.1007/s00125-014-3240-x

DO - 10.1007/s00125-014-3240-x

M3 - Article

C2 - 24771091

AN - SCOPUS:84903518224

VL - 57

SP - 1446

EP - 1455

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 7

ER -